Medtronic CEO Bill Hawkins calls 510(k) reforms a “positive sign”

MDT, Bill Hawkins

Medtronic Inc. (NYSE:MDT) CEO William “Bill” Hawkins reacted positively to changes the Food & Drug Administration announced today for its 510(k) program, calling them a “positive sign” that regulators are open to working more collaboratively with industry but denying that the medical device industry won a round in the fight against stricter regulation.

“I wouldn’t say we’ve won. I wouldn’t say that,” Hawkins told MassDevice. “I would say that we’re working towards a more collaborative and constructive working relationship with the FDA, recognizing that we both have the same common goals to advance innovation that is safe and effective. I think this, in my judgement, is a good sign coming out to the FDA.”

Hawkins told us he’s encouraged by the approach the agency took in deciding the 25 changes it plans to make to the system by which a majority of medical devices are cleared for market. The news might help eliminate some of the uncertainty among medical device investors and stakeholders about changes to the regulatory system, because it shows that the FDA won’t make wholesale changes without hearing from the industry first.

But Hawkins said there is still more work to do in making the medical device review process predictable and consistent.

“That’s still an area where we want to work with the FDA,” he said.

Below is a transcript of our talk with Hawkins and Medtronic’s chief regulatory officer Susan Alpert.

MassDevice: What’s your general reaction to the FDA’s report? Is this a good sign or a bad one for industry?

William Hawkins: I think the best way to summarize is that we’re encouraged by what we heard. It’s very balanced, because it certainly retains the authority of the FDA to ask for more information on more product-specific cases, versus perhaps putting forth changes that would affect a broad general class of products, which is where we were concerned. I think the FDA did a lot of work, which we applaud them for. They were engaged, they listened, they were constructive. It’s a positive sign.

MassDevice: Susan, can you give us an idea of what impact the new de novo regulations for devices with no predicates might have on Medtronic?

Susan Alpert: Until the guidance is out, that’s going to be hard to answer. But they’re going to do some guidance work on de novo and make it available for comment, which will provide a clearer view on what they plan to do and how they plan to move products into and through that process. Until we see that, it’s very difficult to predict.

But what they’ve done in their work so far is demonstrate that they’re going to carefully consider the changes they’re going to make to the product and the way in which we use predicates. Those are very important issues that will impact de novo. We do recognize it will be more than what goes through today.

MassDevice: Do you think this does anything to subdue the lingering uncertainty about the industry that so many in the investment community have complained about?

BH: I do. I’m encouraged. There’s still a lot of uncertainty that affects investors and companies in the industry, but this is a positive indication of where the FDA is moving. And some of the comments coming from Dr. Shuren about what was behind this — that this was to find improvements that would address our competitiveness, that would keep jobs at home, is encouraging.

The other thing that has been a concern for industry is the predictability and the consistency. That’s still an area we want to work with the FDA on.

SA: I think it’s very encouraging that one of the things they’re going to do is the training, very early on, of their staff in providing better guidance and training. That will help industry a lot.

MassDevice: Some of the proposals seemed to come straight off of the industry’s wish list. Do you feel like the med-tech sector won a round?

BH: I don’t think that’s the right word. I wouldn’t say that we’ve won. I would say that we’re working towards a more collaborative and constructive working relationship with the FDA, recognizing that we both have the same common goals to advance innovation that is safe and effective. I think this, in my judgement, is a good sign coming out of the FDA.

SA: This is very balanced. If you look at some of the earlier proposals, they cast a very broad net, where the concern was that many additional products were being pulled in. What they put out today shows much more balance in the application of what they want to do. They’re focusing on the higher-risk products, getting what they need for those products but not pulling everything along, and I think that’s very important.

RSS From Medical Design & Outsourcing

  • MSC Apex Diamond Python and Smart Midsurface speeds modeling to validation
    MSC Software announced a new release of MSC Apex, the company’s award-winning next generation Computer Aided Engineering (CAE) platform. The MSC Apex Diamond Python release introduces: · The fourth release of MSC Apex Modeler is a CAE Specific direct modeling and meshing solution that streamlines CAD clean-up, simplification and meshing workflow. New in this release is […]
  • Quality Metrics: FDA’s plan for a key set of measurements to help ensure manufacturers are producing quality medications
    Editor’s Note: This article is written by Ashley Boam and Mary Malarkey from the “FDA Voice” blog. Boam is an FDA’s acting Director of the Office of Policy for Pharmaceutical Quality, the Office of Pharmaceutical Quality and the Center for Drug Evaluation and Research. Malarkey is an FDA’s Director if the Office of Compliance and Biologics Quality […]
  • MasterControl’s CEO talks EQMS software and new partnerships
    MasterControl offers a quality and compliance software that helps device companies speed time to market and improve their bottom lines. Under Jon’s leadership, the company has blossomed into a market leader and has a unique corporate culture that fosters growth, excellence and quality. In this podcast, MasterControl’s CEO, Jon Beckstrand, will discuss electronic quality management […]
  • BIT Group launches white label IVD solutions
    BIT Group has launched a product line of customizable IVD white label instruments. During recent years, BIT has invested capital and resources developing customizable, ready-to-use IVD systems to address a growing demand. “The IVD market is challenging for our clients,” said Marius Balger, CEO at BIT. “OEM’s must adhere to a growing number of evolving IVD […]
  • Toshiba expands line-up of ARM Cortex-M-based microcontrollers
    Toshiba announced that it has enhanced its current “TX Family” of ARM core-based microcontrollers and started to develop three series of microcontrollers, “TXZ0 series,” “TXZ3 series” and “TXZ4 series,” as part of the “TXZTM Family.” The TXZTM Family is a new collection of flash microcontrollers that support low-power consumption and high-speed operation for IoT and M2M […]
  • Parker Hannifin consolidates, layoffs ahead
    Parker Hannifin plans to consolidate a number of internal divisions, close 2 facilities and expand its Mexican operations, according to an internally distributed letter from Andy Ross, Parker’s engineered materials group president. The company has confirmed the letter was authentic, but has not disclosed how many employees will be affected by the new plans or […]
  • 3-phase current transducer from PEM delivers all-in-one convenience
    The new RCTrms 3-ph current transducer from Power Electronic Measurements (PEM) delivers a convenient, safe and accurate solution for measuring current in three phases. It features a thin, clip-around, flexible sensor coil and provides accurate true rms measurement with 4-20 mA or 0-5 V output, enabling simple installation with PLC’s, SCADA systems or automation equipment. […]
  • Safety alert: Recall on two IV solutions from Baxter
    Baxter International announced it is voluntarily recalling two lots of intravenous (IV) solutions to the hospital and user level due to the potential presence of particulate matter. The particulate matter in each case was determined to be an insect and was identified as a result of a customer complaint. The matter was identified prior to […]
  • TSO3 begins shipment of STERIZONE VP4 Sterilizers to U.S.
    TSO3, a developer in sterilization technology for medical devices in healthcare settings, announced that the company has received purchase orders for multiple devices from the U.S. The orders are the result of the collaborative relationship between Getinge Infection Control, its sales and service provider, and TSO3. “Finally,” said R.M. Rumble, president and CEO of TSO3. “Our Vision is […]
  • Turkish medical company is seeking reseller and OEM partners in the U.S.
    UZUMCU Medical Equipment, one of Turkey’s first and largest manufacturers of medical devices, is seeking reseller and OEM partners in the U.S. The company has an array of FDA-certified OR tables, surgical lights, surgical suction units, electro devices and other medical equipment. “We want to bring our experience with distributors throughout Europe and the Middle […]
  • QImaging introduces new CCD cameras for microscopy with modern software to streamline image capture
    QImaging, a manufacturer of scientific cameras for life science and OEM applications, introduces a new series of Retiga CCD cameras, accompanied by QImaging’s new acquisition software to deliver high-performance tools for microscopy and imaging to researchers at an affordable price. The new QImaging Retiga R1, Retiga R3 and Retiga R6 cameras offer valuable technical features […]

Leave a Reply